TrialBlood advances2018

Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.

Alexander Röth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.